480 Arsenal Way
About Selecta Biosciences
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVPTM) with a range of biologics for rare and serious diseases that require new treatment options. The company's current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company's lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta's SEL-403 product candidate, a combination therapy consisting of SVP-Rapamycin and LMB-100, recently entered a Phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. Selecta's proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP also holds potential in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com and follow @SelectaBio on Twitter.
Stock Symbol: SELB
156 articles with Selecta Biosciences
Selecta Biosciences Reports Third Quarter 2021 Financial Results and Provides Business Update
Selecta Biosciences Announces Top Line Data from the Phase I SEL-399 AAV Empty Capsid Study, Highlighting Potential Benefits of ImmTOR™ in Gene Therapy
Selecta Biosciences, Inc. today announced top-line results from a joint Selecta and AskBio Phase I randomized, placebo controlled, double blind, dose-escalation study to evaluate the potential of its ImmTOR™ platform in mitigating the formation of neutralizing antibodies against an adeno-associated viral serotype 8 (AAV8) serotype capsid used in gene therapies.
Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update
Selecta Biosciences, Inc. today announced that it plans to host a conference call on Tuesday, November 9, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and provide a business update.
Selecta Biosciences and Ginkgo Bioworks Announce Partnership to Advance Treatments for Orphan and Rare Diseases
Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to design novel and improved enzymes with transformative therapeutic potential to advance treatments for orphan and rare diseases.
Selecta Biosciences and Genovis Enter Exclusive License Agreement to Advance Next-Generation IgG Protease in Gene Therapy and Autoimmune Disease
Selecta Biosciences, Inc. today announced a strategic licensing agreement to advance a next-generation IgG protease.
Selecta Biosciences, Inc. today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual Gene Therapy/Editing Summit to be held October 27-28, 2021.
Redosing is a large and growing concern for gene therapy developers and regulators.
Selecta Biosciences, Inc. (NASDAQ: SELB), today announced it will be presenting preclinical data in four posters highlighting its ImmTOR nanoparticle platform and its potential to safely enable repeat vector dosing in gene therapy patients at the 28th Annual Congress of the European Society of Gene & Cell Therapy
A safety concern has forced Takeda Pharmaceutical to suspend the dosing of patients in two Phase II studies of an experimental treatment for narcolepsy.
Selecta Biosciences Announces Strategic Licensing Agreement with Takeda to Develop Next-Generation Gene Therapies for Patients with Lysosomal Storage Disorders
Selecta Biosciences, Inc. today announced that it has entered into a strategic licensing agreement with Takeda Pharmaceutical Company Limited (“Takeda”) to develop targeted, next-generation gene therapies for two indications within the field of lysosomal storage disoorders.
9/24/2021Life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
Selecta Biosciences, Inc. today announced that Company’s Management will participate in a fireside chat and one-on-one investor meetings at the Cantor Virtual Global Healthcare Conference to be held September 27-30, 2021.
Selecta Biosciences, Inc. today announced the appointment of Kevin Tan as chief financial officer.
Selecta and Cyrus' partnership will pair Selecta’s immune-modulating ImmTOR platform with Cyrus’ ability to redesign protein therapeutics through its de novo computational approach.
Selecta Biosciences, Inc. announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.
Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins
Selecta Biosciences, Inc. (NASDAQ: SELB), and Cyrus Biotechnology, Inc., today announced a protein engineering collaboration combining Selecta’s ImmTOR platform with Cyrus’ ability to radically redesign protein therapeutics.
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today reported financial results for the second quarter ended June 30, 2021 and provided a business update.
Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Business Update
Selecta Biosciences, Inc. announced that it plans to host a conference call on Thursday, August 12, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2021 and provide a business update.
Selecta Biosciences, Inc. announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in upcoming investor conferences in August.
Selecta Biosciences Announces Appointment of Jude Samulski, Ph.D. as Gene Therapy Special Advisor and the Publication of Data Evaluating ImmTOR™ with AAV vectors for the treatment of Methylmalonic Acidemia
Selecta Biosciences, Inc. today announced the appointment of world renowned AAV gene therapy pioneer Jude Samulski, Ph.D., as a special advisor to assist with the development of their gene therapy programs.